Pro-Pharmaceuticals, Inc. (OTCBB: PRWP), a bio-pharmaceutical company developing proprietary therapeutic compounds to treat cancer and fibrosis, has entered into a consulting agreement with Perceptive Imagineering, LLC (“Perceptive”) to represent the Company in Central and South America. Starting in Colombia, Perceptive will conduct registration, marketing, sales and support for the licensing and distribution of DAVANAT® throughout the region to treat colorectal cancer in combination with approved chemotherapy drugs. Next steps are to finalize an export license and to select an established partner for distribution. Perceptive also will develop a website for Pro-Pharmaceuticals specifically designed for the Latin American market.
“The collaboration with Perceptive is another deliberate step in our plan to commercialize DAVANAT® on a regional basis,” said Theodore Zucconi, Ph.D., Chief Executive Officer of Pro-Pharmaceuticals. “We continue to pursue partnerships with international distributors as well as with several large international pharmaceutical companies who have established distribution and infrastructure outside the United States. Perceptive is an experienced partner that will enable us to penetrate major markets in South and Central America.”
Perceptive specializes in assisting U.S. medical companies in bringing their products into Latin America. The company is led by its president, Nancy Alvarez, MD. Under her leadership, Perceptive is well-suited for the opportunity to get DAVANAT® approved in Colombia and then branded as the next generation of chemotherapy. Dr. Alvarez has been a frequent guest in Colombian media, appearing on TV regularly while attending the Metropolitan University of Colombia, where she received a degree in general medicine and surgery. Since coming to the United States, Dr. Alvarez has appeared on TV while working in the medical industry.
“We understand that the medical approval process is different in each Central and South American country. We are well-equipped to ensure the execution of a viable commercialization plan in each country that is consistent with the culture and needs of their respective medical systems,” stated Dr. Alvarez. “Our goal is to initiate sales and marketing opportunities for Pro-Pharmaceuticals’ DAVANAT® to be co-administered with 5-FU to treat colorectal cancer patients. This market represents an immediate opportunity for Pro-Pharmaceuticals and we are pleased to represent them.”
No comments:
Post a Comment